Mumbai-based Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India.
The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.
Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.
Glenmark’s Glempa range is designed to cater to diverse patient needs by offering three treatment options that enhance treatment flexibility and effectiveness. Glempa (Empagliflozin 10mg/25mg) serves as a standalone SGLT2 inhibitor to improve glycaemic control while reducing cardiovascular risks. Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) is a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio renal risks. Meanwhile, Glempa M (Empagliflozin 12.5 mg + Metformin 500/1000 mg) combines the benefits of SGLT2 inhibition with the proven efficacy of Metformin, making it an optimal choice for patients needing stronger glycemic control.
With Cardiovascular diseases and diabetes cases on the rise, Glenmark’s Glempa range aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India
